Is Ro 31-8959 Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use Ro 31-8959? Is Ro 31-8959 safe for nursing mother and child? Does Ro 31-8959 extracts into breast milk? Does Ro 31-8959 has any long term or short term side effects on infants? Can Ro 31-8959 influence milk supply or can Ro 31-8959 decrease milk supply in lactating mothers?

• DrLact safety Score for Ro 31-8959 is 5 out of 8 which is considered Unsafe as per our analyses.
• A safety Score of 5 indicates that usage of Ro 31-8959 may cause serious side effects in breastfed baby.
• Our study of different scientific research indicates that Ro 31-8959 may cause moderate to high side effects or may affect milk supply in lactating mother.
• Our suggestion is to use safer alternate options rather than using Ro 31-8959 .
• It is recommended to evaluate the advantage of not breastfeeding while using Ro 31-8959 Vs not using Ro 31-8959 And continue breastfeeding.
• While using Ro 31-8959 Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
• Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Anti-HIV drug. No experience on young infants is available.Mothers must be adviced that transmission of HIV infection through breastfeeding has been documented.

In the United States and other developed countries, HIV-infected mothers should generally not breastfeed their infants. No published information is available on the use of Ro 31-8959 during breastfeeding. In countries in which no acceptable, feasible, sustainable and safe replacement feeding is available, World Health Organization guidelines recommend that all women with an HIV infection who are pregnant or breastfeeding should be maintained on antiretroviral therapy for at least the duration of risk for mother-to-child transmission. Mothers should exclusively breastfeed their infants for the first 6 months of life; breastfeeding with complementary feeding should continue through at least 12 months of life up to 24 months of life.[1] The first choice regimen for nursing mothers is tenofovir, efavirenz and either lamivudine or emtricitabine. If these drugs are unavailable, alternative regimens include: 1) zidovudine, lamivudine and efavirenz; 2) zidovudine, lamivudine and nevirapine; or 3) tenofovir, nevirapine and either lamivudine or emtricitabine. Exclusively breastfed infants should also receive 6 weeks of prophylaxis with nevirapine.[2][3]

Gynecomastia has been reported among men receiving highly active antiretroviral therapy. Gynecomastia is unilateral initially, but progresses to bilateral in about half of cases. No alterations in serum prolactin were noted and spontaneous resolution usually occurred within one year, even with continuation of the regimen.[4][5][6] Some case reports and in vitro studies have suggested that protease inhibitors might cause hyperprolactinemia and galactorrhea in some male patients,[7][8] although this has been disputed.[9] The relevance of these findings to nursing mothers is not known. The prolactin level in a mother with established lactation may not affect her ability to breastfeed